Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Microenvironment
Erschienen in: Cancer Microenvironment 1/2018

04.03.2018 | Review

Role of the Nervous System in Tumor Angiogenesis

verfasst von: Nyanbol Kuol, Lily Stojanovska, Vasso Apostolopoulos, Kulmira Nurgali

Erschienen in: Cancer Microenvironment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The development of cancer involves an intricate process, wherein many identified and unidentified factors play a role. Tumor angiogenesis, growth of new blood vessels, is one of the major prerequisites for tumor growth as tumor cells rely on adequate oxygen and nutrient supply as well as the removal of waste products. Growth factors including VEGF orchestrate the development of angiogenesis. In addition, nervous system via the release of neurotransmitters contributes to tumor angiogenesis. The nervous system governs functional activities of many organs, and, as tumors are not independent organs within an organism, this system is integrally involved in tumor growth and progression via regulating tumor angiogenesis. Various neurotransmitters have been reported to play an important role in tumor angiogenesis.
Literatur
1.
Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286CrossRefPubMed
2.
3.
4.
McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Supplement 1):3–10CrossRefPubMed
5.
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071–1121CrossRefPubMedPubMedCentral
6.
Zibara K, Awada Z, Dib L, El-Saghir J, Al-Ghadban S, Ibrik A, El-Zein N, El-Sabban M (2015) Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo. Sci Rep 5:12598
7.
Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM (2016) Targeted scVEGF/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res 6(1):1–9CrossRef
8.
Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17(3):471–494CrossRefPubMedPubMedCentral
9.
10.
11.
Place AE, Jin Huh S, Polyak K (2011) The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 13(6):227CrossRefPubMedPubMedCentral
12.
Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11):1359–1370CrossRefPubMed
13.
Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H (2015) Nerve–cancer cell cross-talk: a novel promoter of tumor progression. Cancer Res 75(9):1777–1781CrossRefPubMed
14.
Ondicova K, Mravec B (2010) Role of nervous system in cancer aetiopathogenesis. Lancet Oncol 11(6):596–601CrossRefPubMed
15.
Chen H, Liu D, Yang Z, Sun L, Deng Q, Yang S, Qian L, Guo L, Yu M, Hu M, Shi M, Guo N (2014) Adrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk. Endocr Relat Cancer 21(5):783–795CrossRefPubMed
16.
Liu J, Deng G-H, Zhang J, Wang Y, Xia X-Y, Luo X-M, Deng Y-T, He S-S, Mao Y-Y, Peng X-C (2015) The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models. Psychoneuroendocrinology 52:130–142CrossRefPubMed
17.
Deng G-H, Liu J, Zhang J, Wang Y, Peng X-C, Wei Y-Q, Jiang Y (2014) Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model. J Exp Clin Cancer Res 33(1):1–12CrossRef
18.
Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh J-W, Nishimura M (2013) Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia 15(5):502–IN515CrossRefPubMedPubMedCentral
19.
Moreno-Smith M, Lu C, Shahzad MM, Pena GNA, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D (2011) Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 17(11):3649–3659CrossRefPubMedPubMedCentral
20.
Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S (2004) Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10(13):4349–4356CrossRefPubMed
21.
Hoeppner LH, Wang Y, Sharma A, Javeed N, Van Keulen VP, Wang E, Yang P, Roden AC, Peikert T, Molina JR (2015) Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol 9(1):270–281CrossRefPubMed
22.
Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T (2005) γ-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP–dependent regulation of the protein kinase a/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 65(24):11437–11446CrossRefPubMed
23.
Park SH, Kim B-R, Lee JH, Park ST, Lee S-H, Dong SM, Rho SB (2014) GABARBP down-regulates HIF-1α expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways. Cell Signal 26(7):1506–1513CrossRefPubMed
24.
Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Graf R, Clavien P-A (2008) Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 68(13):5152–5158CrossRefPubMed
25.
Speyer CL, Hachem AH, Assi A, DeVries JA, Gorski DH (2013) Metabotropic glutamate receptor-1 as a novel target for the anti-angiogenic treatment of breast cancer. Cancer Res 73(8 Supplement):3895CrossRef
26.
Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS, Mehnert JM, Chen S, Cohen-Sola KA, Goydos JS (2014) Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Res 74(9):2499–2509CrossRefPubMedPubMedCentral
27.
Zhang Q, Tang X, Zhang Z-F, Velikina R, Shi S, Le AD (2007) Nicotine induces hypoxia-inducible factor-1α expression in human lung cancer cells via nicotinic acetylcholine receptor–mediated signaling pathways. Clin Cancer Res 13(16):4686–4694CrossRefPubMedPubMedCentral
28.
Wong HPS, Yu L, Lam EKY, Tai EKK, Wu WKK, Cho C-H (2007) Nicotine promotes colon tumor growth and angiogenesis through β-adrenergic activation. Toxicol Sci 97(2):279–287CrossRefPubMed
29.
Lombardi Mí G, Negroni M, Pelegrina LT, Castro Mí E, Fiszman GL, Azar Mí E, Morgado CC, Sales Mí E (2013) Autoantibodies against muscarinic receptors in breast cancer: their role in tumor angiogenesis. PLoS One 8(2):e57572CrossRef
30.
de la Torre E, Davel L, Jasnis MA, Gotoh T, de Lustig ES, Sales ME (2005) Muscarinic receptors participation in angiogenic response induced by macrophages from mammary adenocarcinoma-bearing mice. Breast Cancer Res 7(3):R345–R352CrossRefPubMedPubMedCentral
31.
Medeiros PJ, Jackson DN (2013) Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis. Peptides 48:106–113CrossRefPubMed
32.
Medeiros PJ, Al-Khazraji BK, Novielli NM, Postovit LM, Chambers AF, Jackson DN, Neuropeptide Y (2012) Stimulates proliferation and migration in the 4T1 breast cancer cell line. Int J Cancer J Int du Cancer 131(2):276–286CrossRef
33.
Alasvand M, Rashidi B, Javanmard SH, Akhavan MM, Khazaei M (2015) Effect of blocking of neuropeptide Y Y2 receptor on tumor angiogenesis and progression in normal and diet-induced obese C57BL/6 mice. Glob J Health Sci 7(7):46883CrossRef
34.
Lu C, Everhart L, Tilan J, Kuo L, Sun CJ, Munivenkatappa RB, Jönsson-Rylander A-C, Sun J, Kuan-Celarier A, Li L (2010) Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 29(41):5630–5642CrossRefPubMedPubMedCentral
35.
Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K (2006) Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 12(4):1201–1207CrossRefPubMed
36.
Nomelini RS, Ribeiro LCDA, Tavares-Murta BM, Adad SJ, Murta EFC (2009) Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors. Mediators Inflamm 2008:186584
37.
Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K (2005) Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8(1):18–28CrossRefPubMed
38.
Sarkar C, Chakroborty D, Basu S (2013) Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 8(1):7–14CrossRef
39.
Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S (2009) Catecholamines regulate tumor angiogenesis. Cancer Res 69(9):3727–3730CrossRefPubMed
40.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939–944CrossRefPubMed
41.
Xie H, Li C, He Y, Griffin R, Ye Q, Li L (2015) Chronic stress promotes oral cancer growth and angiogenesis with increased circulating catecholamine and glucocorticoid levels in a mouse model. Oral Oncol 51(11):991–997CrossRefPubMed
42.
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042–7052CrossRefPubMedPubMedCentral
43.
Madden KS, Szpunar MJ, Brown EB (2011) Beta-adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines. Breast Cancer Res Treat 130(3):747–758CrossRefPubMedPubMedCentral
44.
Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of Jag1 and Notch1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65(18):8530–8537CrossRefPubMed
45.
Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, Reedijk M (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20(6):685–693CrossRefPubMed
46.
Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7(5):569–574CrossRefPubMed
47.
48.
Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S (2008) Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 14(8):2502–2510CrossRefPubMed
49.
Schuller HM (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 9(3):195–205CrossRefPubMed
50.
Egleton RD, Brown KC, Dasgupta P (2009) Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacol Ther 121(2):205–223CrossRefPubMed
51.
Cucina A, Sapienza P, Corvino V, Borrelli V, Mariani V, Randone B, Santoro D'Angelo L, Cavallaro A (2000) Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-beta 1. Surgery 127(3):316–322CrossRefPubMed
52.
Conklin BS, Zhao W, Zhong DS, Chen C (2002) Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol 160(2):413–418CrossRefPubMedPubMedCentral
53.
Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, Shah YH, Shiflett BS, Marcelo AJ, Proper NA, Hardman WE, Egleton RD, Chen YC, Mangiarua EI, Dasgupta P (2012) MG624, an alpha7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 15(1):99–114CrossRefPubMed
54.
Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, Chellappan S (2009) Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 4(10):e7524CrossRefPubMedPubMedCentral
55.
Lee CH, Huang CS, Chen CS, Tu SH, Wang YJ, Chang YJ, Tam KW, Wei PL, Cheng TC, Chu JS, Chen LC, Wu CH, Ho YS (2010) Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst 102(17):1322–1335CrossRefPubMed
56.
Wu C-H, Lee C-H, Ho Y-S (2011) Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 17(11):3533–3541CrossRefPubMed
57.
Dasgupta P, Chellappan SP (2006) Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 5(20):2324–2328CrossRefPubMed
58.
Fiszman GL, Middonno MC, de la Torre E, Farina M, Español AJ, Sales ME (2007) Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. Cancer Biol Ther 6(7):1106–1113CrossRefPubMed
59.
Li L, Kilbourn RG, Adams J, Fidler IJ (1991) Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 51(10):2531–2535PubMed
60.
Cianchi F, Cortesini C, Fantappiè O, Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G, Marzocca C, Perna F, Mazzanti R, Bechi P, Masini E (2003) Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 162(3):793–801CrossRefPubMedPubMedCentral
61.
Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6(7):521–534CrossRefPubMed
62.
Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS (2006) The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 8(7–8):1329–1337CrossRefPubMed
63.
Andrade SP, Hart IR, Piper PJ (1992) Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br J Pharmacol 107(4):1092–1095CrossRefPubMedPubMedCentral
64.
Chu SC, Marks-Konczalik J, Wu H-P, Banks TC, Moss J (1998) Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem Biophys Res Commun 248(3):871–878CrossRefPubMed
65.
Vahora H, Khan MA, Alalami U, Hussain A (2016) The potential role of nitric oxide in halting cancer progression through chemoprevention. J Cancer Prev 21(1):1–12CrossRefPubMedPubMedCentral
66.
Radisky ES, Radisky DC (2015) Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark ed) 20:1144–1163CrossRef
67.
Wangari-Talbot J, Wall BA, Goydos JS, Chen S (2012) Functional effects of GRM1 suppression in human melanoma cells. Mol Cancer Res 10(11):1440–1450CrossRefPubMedPubMedCentral
68.
Xia H, Zhao YN, Yu CH, Zhao YL, Liu Y (2016) Inhibition of metabotropic glutamate receptor 1 suppresses tumor growth and angiogenesis in experimental non-small cell lung cancer. Eur J Pharmacol 783:103–111CrossRefPubMed
69.
He T, Qi F, Jia L, Wang S, Wang C, Song N, Fu Y, Li L, Luo Y (2015) Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p. Cancer Lett 368(1):115–125CrossRefPubMed
70.
Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, Rosser C (2015) Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 34(7):890–901CrossRefPubMed
71.
Shu J, Huang M, Tian Q, Shui Q, Zhou Y, Chen J (2015) Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway. J Mol Histol 46(2):157–171CrossRefPubMed
72.
Sasi SP, Yan X, Enderling H, Park D, Gilbert H-Y, Curry C, Coleman C, Hlatky L, Qin G, Kishore R (2012) Breaking the ‘harmony’of TNF-α signaling for cancer treatment. Oncogene 31(37):4117–4127CrossRefPubMed
73.
Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Wang J (2013) TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis. PLoS One 8(3):e59918CrossRefPubMedPubMedCentral
74.
Lin C-Y, Hung S-Y, Chen H-T, Tsou H-K, Fong Y-C, Wang S-W, Tang C-H (2014) Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells. Biochem Pharmacol 91(4):522–533CrossRefPubMed
75.
Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo K, Li DY, Bikfalvi A, Auguste P (2012) Blocking fibroblast growth factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS One 7(6):e39540CrossRefPubMedPubMedCentral
76.
Wang W-M, Zhao Z-L, Ma S-R, Yu G-T, Liu B, Zhang L, Zhang W-F, Kulkarni AB, Sun Z-J, Zhao Y-F (2015) Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and notch1 in head neck squamous cell carcinoma. PLoS One 10(2):e0119723
77.
Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X (2010) Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Breast Cancer 9:11
78.
Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P (2005) Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 11(17):6190–6197CrossRefPubMed
79.
Sugie S, Mukai S, Yamasaki K, Kamibeppu T, Tsukino H, Kamoto T (2016) Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression. Hum Cell 29(1):22–29CrossRefPubMed
80.
Walsh EM, Kim R, Del Valle L, Weaver M, Sheffield J, Lazarovici P, Marcinkiewicz C (2012) Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesis. Neuro-Oncology 14(7):890–901CrossRefPubMedPubMedCentral
81.
Staniszewska I, Zaveri S, Del Valle L, Oliva I, Rothman VL, Croul SE, Roberts DD, Mosher DF, Tuszynski GP, Marcinkiewicz C (2007) Interaction of α9β1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res 100(9):1308–1316CrossRefPubMed
82.
Vlahakis NE, Young BA, Atakilit A, Hawkridge AE, Issaka RB, Boudreau N, Sheppard D (2007) Integrin α9β1 directly binds to vascular endothelial growth factor (VEGF)-a and contributes to VEGF-A-induced angiogenesis. J Biol Chem 282(20):15187–15196CrossRefPubMed
83.
Staniszewska I, Sariyer IK, Lecht S, Brown MC, Walsh EM, Tuszynski GP, Safak M, Lazarovici P, Marcinkiewicz C (2008) Integrin α9β1 is a receptor for nerve growth factor and other neurotrophins. J Cell Sci 121(4):504–513CrossRefPubMedPubMedCentral
84.
Nilsson UW, Abrahamsson A, Dabrosin C (2010) Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy reduces breast cancer growth in vivo. Clin Cancer Res 16(14):3659–3669CrossRefPubMed
85.
Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L (2005) Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 11(23):8358–8363CrossRefPubMed
86.
Hisai H, Kato J, Kobune M, Murakami T, Miyanishi K, Takahashi M, Yoshizaki N, Takimoto R, Terui T, Niitsu Y (2003) Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 9(13):4852–4859PubMed
87.
Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 86(2):316–324CrossRefPubMed
88.
Gao X, Xu Z (2008) Mechanisms of action of angiogenin. Acta Biochim Biophys Sin 40(7):619–624CrossRefPubMed
89.
de Aguiar RB, Parise CB, Souza CRT, Braggion C, Quintilio W, Moro AM, Navarro Marques FL, Buchpiguel CA, Chammas R, de Moraes JZ (2016) Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings. Cancer Lett 371(2):151–160CrossRefPubMed
90.
Lai KC, Liu CJ, Lin TJ, Mar AC, Wang HH, Chen CW, Hong ZX, Lee TC (2016) Blocking TNF-alpha inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells. Cancer Lett 370(2):207–215CrossRefPubMed
91.
92.
Kataoka H, Miyata S, Uchinokura S, Itoh H (2003) Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 22(2–3):223–236CrossRefPubMed
93.
94.
Djordjevic S, Driscoll PC (2013) Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov Today 18(9–10):447–455CrossRefPubMed
95.
Li L, Jiang X, Zhang Q, Dong X, Gao Y, He Y, Qiao H, Xie F, Xie X, Sun X (2016) Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors. J Exp Clin Cancer Res 35(1):16CrossRefPubMedPubMedCentral
Metadaten
Titel
Role of the Nervous System in Tumor Angiogenesis
verfasst von
Nyanbol Kuol
Lily Stojanovska
Vasso Apostolopoulos
Kulmira Nurgali
Publikationsdatum
04.03.2018
Verlag
Springer Netherlands
Erschienen in
Cancer Microenvironment / Ausgabe 1/2018
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-018-0207-3

Weitere Artikel der Ausgabe 1/2018

Cancer Microenvironment 1/2018 Zur Ausgabe

Short Communication

Three-Dimensional Cellular Arrangement in Epithelial Ovarian Cancer Cell Lines TOV-21G and SKOV-3 is Associated with Apoptosis-Related miRNA Expression Modulation

Commentary

Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential

Original Article

Positive Correlation between Matrix Metalloproteinases and Epithelial-to-Mesenchymal Transition and its Association with Clinical Outcome in Bladder Cancer Patients

Original Article

Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations

Original Article

The Influence of Breast Tumour-Derived Factors and Wnt Antagonism on the Transformation of Adipose-Derived Mesenchymal Stem Cells into Tumour-Associated Fibroblasts

Original Article

Extracellular ATP is Differentially Metabolized on Papillary Thyroid Carcinoma Cells Surface in Comparison to Normal Cells

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen